Eagerly awaited results of the largest-ever study of psilocybin were announced Tuesday, with Compass Pathways revealing the psychedelic drug was highly efficacious as a therapy for treatment-resistant depression. Still, the company’s stock price dropped 16.4% by the close of trading, perhaps because of safety concerns among investors.
The Phase 2b study is the largest randomized, controlled, double-blind trial of psilocybin, the psychedelic compound in magic mushrooms. The company said it found that patients who were given the highest dose, 25 milligrams, had a significant decrease in depressive symptoms compared to those given 1 milligram, which is such a low dose it functions as a placebo.
Overall, 29.1% of patients in the highest-dose group were in remission three weeks after treatment, compared to 7.6% of those in the control group, and more than a quarter of the patients in the 25-milligram arm were still in remission three months after treatment.
advertisement
Those who received the highest dose also experienced an average reduction on a measure of clinical depression (the Montgomery-Asberg Depression Rating Scale) that was 6.6 points greater than those who took 1 milligram. Other patients were given a 10-milligram dose, but there was not a statistically significant impact for those patients compared with the 1-milligram arm.
“Everyone agrees such a result hasn’t been seen before in depression research, so we’re incredibly happy with that result,” said Lars Christian Wilde, co-founder and president of Compass.
advertisement
Boris Heifets, a neuroscience researcher at Stanford who studies psychedelics and was not part of the study, agreed the results are “super promising.” The effectiveness of psilocybin at three weeks, according to Compass’ study, is roughly comparable to the effects of ketamine at one day, according to a smaller 2013 study, he added, which suggests the benefits of psilocybin hold up well over time. “We’re still missing a lot of the detailed data,” he added, but the summary results are “pretty good news.”
The study, which enrolled 233 patients at multiple sites across Europe and North America, is the most rigorous trial on psilocybin for treatment-resistant depression and adds considerable weight to earlier, smaller studies of the drug that were also promising. The U.S. Food and Drug Administration has granted Compass Pathways’ treatment breakthrough therapy designation, meaning the drug approval process will be accelerated if studies continue to show positive results. Compass is working toward starting a Phase 3 trial next year; current results suggest it’ll likely use a 25-milligram dose, but Wilde said that decision will be made following conversations with regulators.
Read more:Psilocybin trial finds psychedelic is effective in treating depression – STAT